EHA | European Hematology Association
EHA 2026
EHA 2026: Germline Testing Beyond Family History in AML and MDS
/ Panagiotis Baliakas
EHA 2026: Teclistamab Outcomes in High-Risk Extramedullary Myeloma
/ Astrid Hundebøll Torpe
EHA 2026: Increased Risk of Psychotropic Drug Use Observed in Patients with Mastocytosis
/ Maren Poulsgaard Jørgensen
EHA 2026: Comparable Outcomes with Reduced-Dose Treosulfan
/ Johanne Skovgaard Schovsbo
EHA 2026: Circulating Tumor Plasma Cells Predict Progression in Smoldering Myeloma
/ Sigrun Thorsteinsdottir
EHA 2025
EHA 2024
Promising Avenues for the Development of Personalized Treatment for FVII Deficiency
/ Maria Eugenia Chollet
An Excellent Target with a Wide Therapeutic Window in del(5q) Myeloid Malignancies
/ Sergio Martinez Høyer
Development of Prediction Models for Survival among Hodgkin Lymphoma Patients
/ Rasmus Rask Kragh Jørgensen
Better Predictor of Treatment Efficacy of Myelodysplastic Syndromes
/ Ângela Sofia Gerós Mesquita












































